OncoCyte (NASDAQ:OCX) Receives New Coverage from Analysts at StockNews.com

StockNews.com initiated coverage on shares of OncoCyte (NASDAQ:OCX) in a research note released on Tuesday morning. The brokerage issued a sell rating on the stock.

Separately, Needham & Company LLC reissued a buy rating and set a $4.25 price objective on shares of OncoCyte in a research report on Friday, August 9th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, OncoCyte presently has an average rating of Hold and a consensus price target of $4.06.

OncoCyte Price Performance

Shares of OCX opened at $3.12 on Tuesday. The firm’s fifty day simple moving average is $3.07 and its two-hundred day simple moving average is $2.93. OncoCyte has a 12 month low of $2.08 and a 12 month high of $4.34.

OncoCyte (NASDAQ:OCX) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.36) earnings per share (EPS) for the quarter. The company had revenue of $0.10 million for the quarter. OncoCyte had a negative return on equity of 149.88% and a negative net margin of 3,558.46%.

Insider Activity at OncoCyte

In other OncoCyte news, major shareholder Broadwood Partners, L.P. purchased 1,315,339 shares of the company’s stock in a transaction that occurred on Wednesday, October 2nd. The shares were acquired at an average price of $2.95 per share, with a total value of $3,880,250.05. Following the transaction, the insider now owns 6,244,405 shares in the company, valued at $18,420,994.75. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other OncoCyte news, major shareholder Broadwood Partners, L.P. purchased 1,315,339 shares of the company’s stock in a transaction that occurred on Wednesday, October 2nd. The shares were acquired at an average price of $2.95 per share, with a total value of $3,880,250.05. Following the transaction, the insider now owns 6,244,405 shares in the company, valued at $18,420,994.75. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Andrea S. James purchased 33,670 shares of the company’s stock in a transaction that occurred on Wednesday, October 2nd. The stock was acquired at an average cost of $2.97 per share, for a total transaction of $99,999.90. Following the transaction, the chief financial officer now owns 33,670 shares in the company, valued at $99,999.90. The disclosure for this purchase can be found here. 1.94% of the stock is owned by insiders.

About OncoCyte

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.